Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A fourth subsidiary of OxStem Ltd, an Oxford spin-out co-founded by Professor Steve Davies and Professor Angela Russell has been launched.

 OxStem Cardio, co-founded with Prof. Roger Patient (Professor of Developmental Genetics Weatherall Institute of Molecular Medicine) and Professor Paul Riley (British Heart Foundation Professor of Regenerative Medicine), aims to identify drugs that will restore lost tissue following a heart attack by inducing cardiovascular regeneration, in order to improve cardiac function. This collaborative project will be funded within the University over the next three years following OxStem’s record £16.9M initial fundraise earlier this year.

Similar stories

Tribute to Sir Wilfrid Le Gros Clark FRS displayed in Sherrington

The bronze portrait bust was originally presented to the Department of Human Anatomy to mark the occasion of Sir Wilfrid Le Gros Clark's silver jubilee as Dr Lee's Professor of Anatomy.

Can humans hibernate?

Illuminating new TEDx Talk from Professor of Sleep Physiology Vladyslav Vyazovskiy

Professor Sir Chris Whitty brings greater understanding of epidemics to Oxford

Chief Medical Officer of England Professor Sir Chris Whitty KCB FMedSci delivers the Sherrington Prize Lecture: Public Understanding of Science to an audience of Oxford staff and students.

New insights into chemogenetic designer drugs to enhance our study of behaviour

A collaborative team of researchers in DPAG and Pharmacology led by Dr Lukas Krone have uncovered striking new data demonstrating that two widely used designer drugs used to turn populations of neurons on and off in the brain cause unexpected effects on sleep. These results demonstrate a critical need to improve chemogenetic approaches in behavioural studies.

Unlocking the Secrets of cAMP Signalling in the Heart: A Pathway to Targeted Therapeutics

A new Zaccolo group study has revealed key new insights into the role of cAMP signalling in both healthy and disease settings within the heart. They have identified new cAMP nanodomains in cardiac muscle cells that have far reaching implications for the treatment of heart disease.